Tempus AI, Inc. TEM
Nov 13, 2026, 1:17 PM EST
- YTD
- +18.07%
- 1 year
- +2.62%
- Market cap
- 12.73B
- Revenue (ttm)
- 1.51B
- Profit margin
- -12.54%
- EPS (ttm)
- -1.06
- Shares out
- 177.36M
- Forward P/E
- -1918.84
- YTD return
- +18.07%
- 1-year return
- +2.62%
- Volume
- 2.96M
- Avg volume
- 7.32M
- Open
- 75.65
- Previous close
- 75.89
- Day's range
- 68.48 – 75.72
- 52-week range
- 41.55 – 85.08
- Beta
- 3.61
- Analysts
- Buy
- Price target
- 89.56 (+28.5%)
- Earnings date
- Feb 23, 2027
5D -10.64 (-13.23%)
Key statistics
- Enterprise value
- 15.28B
- PEG ratio
- 0.00
- Price / sales
- 9.17
- Price / book
- 27.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 23.10%
- Free cash flow
- 41.29M
- Total cash
- 637.35M
- Total debt
- 1.43B
- Return on equity
- -37.55%
- Short % of float
- 24.09%
- 50-day average
- 72.42
- 200-day average
- 57.35
Analyst view
Consensus: buy
- Target (low)
- 70.00
- Target (mean)
- 89.56
- Target (high)
- 120.00
- Strong buy2
- Buy8
- Hold10
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 0.03095.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 0.06 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | -0.0937 | 0.07 | +0.16 | +174.71% |
| Jul 30, 2026 | Jun 30, 2026 | -0.14281 | -0.04 | +0.10 | +71.99% |
| May 5, 2026 | Mar 31, 2026 | -0.21 | -0.13 | +0.08 | +38.10% |
| Feb 24, 2026 | Dec 31, 2025 | -0.04384 | -0.04 | 0.00 | +8.76% |
| Nov 4, 2025 | Sep 30, 2025 | -0.17228 | -0.11 | +0.06 | +36.15% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | Freedom Capital Markets | main | Hold | Hold |
| Nov 3, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 3, 2026 | Baird | main | Outperform | Outperform |
| Nov 3, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Nov 3, 2026 | Jefferies | up | Underperform | Hold |
| Nov 3, 2026 | BTIG | main | Buy | Buy |
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- tempus.com
News
Arizona Eagle Mining Corp. Announces Completion of High Resolution TEM Geophysical Survey at the Eagle Project and Provides Update on McCabe Mine Reopening Studies 
Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting 
Tempus’ Partner Blood Cancer United Launches Dare To Dream REALworld: AML, Patient-Centered Initiative Co-Founded With Rally Foundation For Childhood Cancer Research 
Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer 
SOTERIA Precision Medicine Foundation Partners With Tempus To Provide Personalized, Data-Driven Cancer Treatment Insights, Genomic Sequencing To U.S. Military 
SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer 
CNH Industrial, Planet Labs, Ferguson Enterprises And Other Big Stocks Moving Higher On Monday 
Tempus AI: Q3 Strengthens The Platform Thesis, But Cash Returns Still Need To Catch Up 
Nancy Pelosi Isn't Running for Re-Election in 2026 Midterms: Say Goodbye to Her Stock Picks in Two Months 
Jefferies Upgrades Tempus AI to Hold, Raises Price Target to $70
Your note
Sign in to keep a note on TEM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARTOLUCCI RYAN M | Officer | Sale | Aug 17, 2026 | 67,866 |
| FUKUSHIMA RYAN | Officer | Stock Award(Grant) | Nov 1, 2026 | 678,257 |
| KEYWELL BRADLEY A | Beneficial Owner of more than 10% of a Class of Security | Sale | Jan 16, 2025 | 0 |
| LEFKOFSKY ERIC PAUL | Chief Executive Officer | Sale | Oct 26, 2026 | 0 |
| LEONSIS THEODORE J | Director | Stock Award(Grant) | May 20, 2026 | 88,180 |
| PHELPS ERIK J. | Officer | Sale | Feb 18, 2026 | 79,816 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK Investment Management, LLC | 5.65% | 10,022,634 | 760.62M | Jun 29, 2026 |
| Blackrock Inc. | 4.67% | 8,291,053 | 629.21M | Jun 29, 2026 |
| BAILLIE GIFFORD & CO | 3.90% | 6,911,932 | 524.55M | Sep 29, 2026 |
| Softbank Group Corporation | 3.05% | 5,405,406 | 410.22M | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 2.81% | 4,989,062 | 378.62M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 2.81% | 4,988,038 | 378.54M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Innovation ETF | 2.76% | 4,890,251 | 371.12M | Oct 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.03% | 3,600,815 | 273.27M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.47% | 2,602,554 | 197.51M | Jun 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.47% | 2,606,737 | 197.83M | Oct 30, 2026 |
| VANGUARD WORLD FUND-Vanguard U.S. Growth Fund | 1.09% | 1,934,556 | 146.81M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 0.85% | 1,502,388 | 114.02M | Jun 29, 2026 |